Beijing Kenuo Pharmaceutical Technology

Beijing Kenuo Pharmaceutical Technology is a Chinese biopharmaceutical company and a subsidiary of Lee's Pharmaceutical. The company is primarily focused on the development of innovative drug delivery systems, specifically the Staccato® thermal aerosol technology platform licensed from Alexza Pharmaceuticals. Its lead program is a Fentanyl aerosol inhalation (ZK05) designed for the rapid, non-invasive treatment of cancer breakthrough pain, which is currently in Phase 2 clinical trials in China. By utilizing the Staccato device, the company aims to provide a fast-acting alternative to traditional injectable or transmucosal pain management therapies. Beijing Kenuo is headquartered in Beijing and leverages the R&D and commercialization infrastructure of its parent company to address unmet medical needs in the specialty medicine market.